Journey Medical Corporation
NASDAQ:DERMDrug Manufacturers - Specialty & Generic
+$0.06 today
- Market cap
- $104.15M
- Beta
- 1.10
- P/E (TTM)
- -17.0
- EPS (TTM)
- -$0.35
Volume 0.25M
Average 0.28M
DERM Net Income
Bottom-line profit after all expenses, interest, and taxes.
Journey Medical CorporationNASDAQ: DERM
Net Income · Q1 FY2026 · quarter ended Mar 2026
Net income remains negative
Q1 FY2026 net income was -$2.23M, compared with -$4.07M a year earlier. Trailing-twelve-month net income was -$9.59M.
Context
- Net income amounted to 18.5% of revenue in FY2025, down 7.7 pp from a year earlier.
- Net income grew in size in 1 of the last 3 fiscal years.
What to watch
Whether net income reaches the consensus estimate from 2 analysts of -$3.9M (+65.9%) for the fiscal year ending Dec 2026, a step up from the +22.1% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$2.23M-78.8% QoQ
- Last fiscal yearDec 2025
- -$11.43M+22.1% YoY
- LTMMar 2026
- -$9.59M-15.5% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +45.2% | +83.4% | +38.1 pp |
| 1 year | +22.1% | +65.9% | +43.8 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the income statement
- Latest · FY2025
- (11.43M) USD
- Year-over-year change
- +22.1%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (11.43M) | +22.1% |
| FY2024 | 2024-12-31 | (14.67M) | -280.8% |
| FY2023 | 2023-12-31 | (3.85M) | +87.0% |
| FY2022 | 2022-12-31 | (29.63M) | +32.7% |
| FY2021 | 2021-12-31 | (43.99M) | — |
Net Income vs competitors
How DERM compares with its peers on the latest reported figures
- Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -15.5% is the 3rd highest of 10, against a peer median of -84.7%.
- Net income amounts to 14.8% of revenue for DERM, versus a peer median of 180.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | -$8.38M USD | +42.0% | — | 16.4% | |
| LTM Mar 2026 | -$9.59M USD | -15.5% | — | 14.8% | |
| LTM Mar 2026 | -CA$25.23M CAD | -249.4% | — | 9.2% | |
| LTM Mar 2026 | -$26.11M USD | -23.0% | — | 180.3% | |
| LTM Mar 2026 | -$54.64M USD | +17.6% | — | 167.0% | |
| LTM Mar 2026 | -$75.07M USD | -134.9% | — | 66.4% | |
| LTM Mar 2026 | -€86.12M EUR | -23.5% | — | 527.8% | |
| LTM Mar 2026 | -$136.85M USD | -947.5% | — | 1427.1% | |
| LTM Mar 2026 | -$151.77M USD | -296.2% | — | 8550.6% | |
| FY2025 | -€340.16M EUR | -84.7% | — | 7587.8% | |
| Peer median (excluding DERM) | — | -84.7% | — | 180.3% | |
Competitors are the stored peer set for DERM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 63.13M | 73.67M | 79.18M | 56.13M | 61.86M |
| Cost of Revenue | 32.08M | 30.78M | 26.66M | 20.88M | 25.18M |
| Gross Profit | 31.05M | 42.89M | 52.52M | 35.26M | 36.68M |
| Gross Margin | 49.2% | 58.2% | 66.3% | 62.8% | 59.3% |
| Research & Development | 16.56M | 10.94M | 7.54M | 9.86M | 480K |
| Selling, General & Admin | 39.83M | 59.47M | 43.91M | 40.2M | 44.37M |
| Operating Expenses | 65.93M | 70.41M | 54.59M | 48.93M | 44.85M |
| Depreciation & Amortization | 2.56M | 4.37M | 3.86M | 3.52M | 4.35M |
| EBITDA | (32.77M) | (23.18M) | 1.92M | (8.4M) | (3.33M) |
| EBITDA Margin | -51.9% | -31.5% | 2.4% | -15.0% | -5.4% |
| Operating Income | (34.88M) | (27.52M) | (2.07M) | (13.68M) | (8.17M) |
| Operating Margin | -55.2% | -37.4% | -2.6% | -24.4% | -13.2% |
| Interest Income | 2K | 60K | 322K | 757K | 589K |
| Interest Expense | 7.03M | 2.02M | 1.7M | 2.7M | 3.7M |
| Other Income / Expenses | (7.48M) | (2.05M) | (1.56M) | (934K) | (3.2M) |
| Income Before Tax | (42.36M) | (29.57M) | (3.63M) | (14.61M) | (11.37M) |
| Pre-Tax Margin | -67.1% | -40.1% | -4.6% | -26.0% | -18.4% |
| Income Tax Expense | 1.63M | 63K | 221K | 61K | 60K |
| Net Income | (43.99M) | (29.63M) | (3.85M) | (14.67M) | (11.43M) |
| Net Margin | -69.7% | -40.2% | -4.9% | -26.1% | -18.5% |
| EPS (Basic) | (2.54) | (1.69) | (0.21) | (0.72) | (0.47) |
| EPS (Diluted) | (2.54) | (1.69) | (0.21) | (0.72) | (0.47) |
| Weighted Avg Shares | 17.32M | 17.53M | 18.23M | 20.43M | 24.5M |
| Weighted Avg Shares (Diluted) | 17.32M | 17.53M | 18.23M | 20.43M | 24.5M |
Journey Medical Corporation
NASDAQ:DERM
Intrinsic Alpha fair value
Locked
Current Price
$3.69
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.